US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
WO1996040648A1
(en)
*
|
1995-06-07 |
1996-12-19 |
Sugen, Inc. |
Quinazolines and pharmaceutical compositions
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
CO4940469A1
(es)
|
1997-03-05 |
2000-07-24 |
Sugen Inc |
Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6051593A
(en)
*
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6395734B1
(en)
|
1998-05-29 |
2002-05-28 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
AU760039B2
(en)
|
1998-12-17 |
2003-05-08 |
F. Hoffmann-La Roche Ag |
4-aryloxindoles as inhibitors of JNK protein kinases
|
ES2301255T3
(es)
*
|
1998-12-17 |
2008-06-16 |
F. Hoffmann-La Roche Ag |
4,5-pirazinaxindoles como inhibidores de proteinoquinasas.
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
AU770375B2
(en)
|
1998-12-17 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular CDK2
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
JP2002540096A
(ja)
*
|
1999-03-24 |
2002-11-26 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としてのインドリノン化合物
|
JP2000281588A
(ja)
*
|
1999-03-30 |
2000-10-10 |
Sankyo Co Ltd |
ガンの予防又は治療薬及びそのスクリーニング方法
|
AU4556800A
(en)
*
|
1999-04-27 |
2000-11-10 |
Smithkline Beecham Plc |
Novel treatment
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
US20020010203A1
(en)
|
1999-12-22 |
2002-01-24 |
Ken Lipson |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
US6339100B1
(en)
*
|
1999-12-29 |
2002-01-15 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting mastocytosis
|
AU2001236720A1
(en)
*
|
2000-02-05 |
2001-08-14 |
Bemis, Guy |
Compositions useful as inhibitors of erk
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
CA2410509A1
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
CA2417500C
(en)
*
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
US6720332B2
(en)
|
2000-09-01 |
2004-04-13 |
Smithkline Beecham Corporation |
Oxindole derivatives
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
EP1512413A3
(en)
|
2001-01-16 |
2009-09-23 |
Glaxo Group Limited |
Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
|
US7186745B2
(en)
|
2001-03-06 |
2007-03-06 |
Astrazeneca Ab |
Indolone derivatives having vascular damaging activity
|
US6599902B2
(en)
|
2001-05-30 |
2003-07-29 |
Sugen, Inc. |
5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
DE10134196B4
(de)
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
ATE343575T1
(de)
*
|
2001-09-27 |
2006-11-15 |
Smithkline Beecham Corp |
Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
|
US20030119839A1
(en)
*
|
2001-12-13 |
2003-06-26 |
Nan-Horng Lin |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
GB0206861D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Medicaments
|
US6541504B1
(en)
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
MXPA04009434A
(es)
*
|
2002-04-03 |
2005-01-25 |
Allergan Inc |
(3z)-3- (3 -hidroisobenzofuran- 1-iliden) -1, 3-dihidro- 2h-indol -2-onas como inhibidores de cinasa.
|
US20050176740A1
(en)
*
|
2002-04-08 |
2005-08-11 |
Spector Neil L. |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
AU2003250701A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
AU2003288899B2
(en)
*
|
2002-08-23 |
2009-09-03 |
Novartis Vaccines And Diagnostics, Inc. |
Benzimidazole quinolinones and uses thereof
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US8673924B2
(en)
|
2002-09-04 |
2014-03-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
ES2346204T3
(es)
|
2002-09-04 |
2010-10-13 |
Schering Corporation |
Pirazolopirimidinas adecuadas para el tratamiento de enfermedades cancerosas.
|
ES2298563T3
(es)
*
|
2002-10-09 |
2008-05-16 |
Critical Outcome Technologies, Inc. |
Inhibidores de proteinas tirosina cinasas.
|
EP1565187A4
(en)
*
|
2002-11-13 |
2010-02-17 |
Novartis Vaccines & Diagnostic |
CANCER TREATMENT METHODS AND RELATED METHODS
|
WO2004050681A2
(en)
*
|
2002-11-15 |
2004-06-17 |
Exelixis, Inc. |
Kinase modulators
|
US20050019366A1
(en)
*
|
2002-12-31 |
2005-01-27 |
Zeldis Jerome B. |
Drug-coated stents and methods of use therefor
|
WO2004064733A2
(en)
*
|
2003-01-15 |
2004-08-05 |
Board Of Regents, University Of Texas System |
The use of c-raf inhibitors for the treatment of neurodegenerative diseases
|
US7875616B2
(en)
|
2003-05-27 |
2011-01-25 |
Haegerkvist Robert Per |
Use of tyrosine kinase inhibitor to treat diabetes
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
ATE435015T1
(de)
*
|
2003-10-16 |
2009-07-15 |
Novartis Vaccines & Diagnostic |
Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
|
JP4724665B2
(ja)
*
|
2003-11-07 |
2011-07-13 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
キノリノン化合物を合成する方法
|
WO2005068424A1
(en)
*
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
JPWO2005080392A1
(ja)
*
|
2004-02-19 |
2007-08-02 |
武田薬品工業株式会社 |
ピラゾロキノロン誘導体およびその用途
|
CA2556872C
(en)
*
|
2004-02-20 |
2015-05-12 |
Chiron Corporation |
Modulation of inflammatory and metastatic processes
|
DE102004012070A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
SG176463A1
(en)
|
2005-02-22 |
2011-12-29 |
Univ Michigan |
Small molecule inhibitors of mdm2 and uses thereof
|
MX2007014206A
(es)
*
|
2005-05-13 |
2008-02-07 |
Novartis Ag |
Metodos para tratar cancer resistente a los farmacos.
|
KR101368519B1
(ko)
|
2005-05-23 |
2014-02-27 |
노파르티스 아게 |
결정형 및 기타 형태의 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온 락트산염
|
PE20070335A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
CA2627544C
(en)
*
|
2005-11-29 |
2015-07-07 |
Novartis Ag |
Formulations of quinolinones for the treatment of cancer
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
WO2007097937A1
(en)
|
2006-02-16 |
2007-08-30 |
Schering Corporation |
Pyrrolidine derivatives as erk inhibitors
|
ATE459338T1
(de)
*
|
2006-07-21 |
2010-03-15 |
Novartis Ag |
Formulierungen für benzimidazolylpyridylether
|
CA2662508A1
(en)
*
|
2006-09-19 |
2008-07-10 |
Novartis Ag |
Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
|
US8034815B2
(en)
|
2007-01-11 |
2011-10-11 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
US20110129550A1
(en)
*
|
2007-02-16 |
2011-06-02 |
Connie Erickson-Miller |
Cancer treatment method
|
UY30915A1
(es)
*
|
2007-02-16 |
2008-09-02 |
Smithkline Beecham Corp |
Método de tratamiento de canceres
|
US20110160130A1
(en)
*
|
2007-02-16 |
2011-06-30 |
Connie Erickson-Miller |
Cancer treatment method
|
WO2008134124A1
(en)
*
|
2007-04-30 |
2008-11-06 |
The Uab Research Foundation |
Ul97 inhibitors for treatment of proliferative disorders
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
AR066845A1
(es)
|
2007-06-05 |
2009-09-16 |
Takeda Pharmaceutical |
Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
|
EP2181987B9
(en)
|
2007-08-23 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
|
EP2184285B1
(en)
|
2007-08-29 |
2015-11-04 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
CA2736177A1
(en)
*
|
2007-09-06 |
2009-03-12 |
Boston Biomedical, Inc. |
Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
|
US8530508B2
(en)
*
|
2007-10-09 |
2013-09-10 |
Glaxosmithkline Llc |
Thrombopoietin receptor agonist (TpoRA) kills acute human myeloid leukemia cells
|
CA2709536C
(en)
|
2007-12-21 |
2016-05-31 |
University Health Network |
Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
|
EP2225226B1
(en)
|
2007-12-26 |
2016-08-17 |
Critical Outcome Technologies, Inc. |
Compounds and their use in a method for treatment of cancer
|
CA2714479A1
(en)
|
2008-02-21 |
2009-08-27 |
Schering Corporation |
Compounds that are erk inhibitors
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
JP5743897B2
(ja)
|
2008-11-20 |
2015-07-01 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC |
化合物
|
US8697874B2
(en)
|
2008-12-01 |
2014-04-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
EP2364314B1
(en)
|
2008-12-09 |
2014-03-12 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
SG172926A1
(en)
|
2009-01-30 |
2011-08-29 |
Glaxosmithkline Llc |
Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
|
WO2010100127A1
(en)
|
2009-03-04 |
2010-09-10 |
Novartis Ag |
Disubstituted imidazole derivatives as modulators of raf kinase
|
ES2465971T3
(es)
|
2009-04-06 |
2014-06-09 |
University Health Network |
Inhibidores de quinasa y método para tratar cáncer con los mismos
|
JP5554833B2
(ja)
|
2009-05-20 |
2014-07-23 |
グラクソスミスクライン エルエルシー |
Pi3キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
|
MX2012002066A
(es)
|
2009-08-17 |
2012-03-29 |
Intellikine Inc |
Compuestos heterociclicos y usos de los mismos.
|
HUE029098T2
(en)
|
2009-08-21 |
2017-02-28 |
Novartis Ag |
To treat lapatinib cancer
|
IN2012DN02596A
(US06268391-20010731-C00042.png)
|
2009-08-26 |
2015-08-28 |
Cylene Pharmaceuticals Inc |
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
NO2477987T3
(US06268391-20010731-C00042.png)
|
2009-09-14 |
2018-06-09 |
|
|
HUE060206T2
(hu)
|
2009-10-16 |
2023-02-28 |
Novartis Ag |
MEK gátlót és B-Raf gátlót tartalmazó kombináció
|
JP5694345B2
(ja)
|
2009-10-22 |
2015-04-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
Toll様受容体の調節因子
|
US20150018301A1
(en)
*
|
2009-11-06 |
2015-01-15 |
The Johns Hopkins University |
LRRK-2-Mediated Neuronal Toxicity
|
CN102770426B
(zh)
|
2010-02-05 |
2016-03-23 |
诺瓦提斯公司 |
作为蛋白激酶抑制剂的化合物和组合物
|
BR112012024380A2
(pt)
|
2010-03-25 |
2015-09-15 |
Glaxosmithkline Llc |
compostos químicos
|
EP3235818A3
(en)
|
2010-04-01 |
2018-03-14 |
Critical Outcome Technologies, Inc. |
Compounds for the treatment of hiv
|
DK2556071T3
(en)
|
2010-04-06 |
2016-12-12 |
Univ Health Network |
Kinase inhibitors AND THEIR USE FOR THE TREATMENT OF CANCER
|
KR20140117684A
(ko)
|
2010-06-25 |
2014-10-07 |
노파르티스 아게 |
단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
|
US20130172378A1
(en)
|
2010-09-14 |
2013-07-04 |
Glaxosmithkline Llc |
Combination of BRAF and VEGF Inhibitors
|
EP2624696B1
(en)
|
2010-10-06 |
2016-12-21 |
Glaxosmithkline LLC |
Benzimidazole derivatives as pi3 kinase inhibitors
|
GB201112607D0
(en)
|
2011-07-22 |
2011-09-07 |
Glaxo Group Ltd |
Novel compounds
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產(第二)有限公司 |
新穎醫藥組成物
|
EP2663189B1
(en)
|
2011-01-11 |
2018-07-04 |
Novartis AG |
Combination of bortezomib with afuresertib and use thereof in the treatment of cancer
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
CN108542906A
(zh)
|
2011-11-11 |
2018-09-18 |
诺华股份有限公司 |
治疗增生性疾病的方法
|
CN103945831A
(zh)
|
2011-11-23 |
2014-07-23 |
诺华股份有限公司 |
医药制剂
|
US20150023953A1
(en)
|
2012-01-31 |
2015-01-22 |
Smithkline Beecham (Cork) Limited |
Method of treating cancer
|
WO2013143597A1
(en)
|
2012-03-29 |
2013-10-03 |
Glaxo Group Limited |
Demethylase enzymes inhibitors
|
CN104955824B
(zh)
|
2012-11-20 |
2017-09-22 |
豪夫迈·罗氏有限公司 |
作为含t790m的egfr突变体的抑制剂的氨基嘧啶化合物
|
IL266415B2
(en)
|
2012-11-30 |
2024-03-01 |
Glaxosmithkline Llc |
Innovative pharmaceutical composition
|
RU2015132907A
(ru)
|
2013-01-09 |
2017-02-14 |
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед |
Комбинация
|
ES2651331T3
(es)
|
2013-01-10 |
2018-01-25 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Inhibidores de la sintasa de ácidos grasos
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
KR20150127249A
(ko)
*
|
2013-03-13 |
2015-11-16 |
보스톤 바이오메디칼, 인크. |
암 치료를 위한 암 줄기세포 경로 키나아제의 저해제로서 3-(아릴 또는 헤테로아릴)메틸렌인돌린-2-온 유도체
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
EP3003282A1
(en)
|
2013-06-03 |
2016-04-13 |
Novartis AG |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
WO2014210354A1
(en)
|
2013-06-28 |
2014-12-31 |
Genentech, Inc. |
Azaindazole compounds as inhibitors of t790m containing egfr mutants
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
MX2016004265A
(es)
|
2013-10-01 |
2016-07-08 |
Novartis Ag |
Combinacion.
|
CN105792825A
(zh)
|
2013-10-01 |
2016-07-20 |
诺华股份有限公司 |
组合
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
ES2908200T3
(es)
|
2013-10-18 |
2022-04-28 |
Univ Health Network |
Tratamiento para el cáncer de páncreas
|
AU2014362995A1
(en)
|
2013-12-12 |
2016-05-26 |
Novartis Ag |
Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
|
US20160361309A1
(en)
|
2014-02-26 |
2016-12-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
CA2942204A1
(en)
|
2014-03-12 |
2015-09-17 |
Novartis Ag |
Combination comprising a btk inhibitor and an akt inhibitor
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
NZ728072A
(en)
|
2014-07-11 |
2018-06-29 |
Gilead Sciences Inc |
Modulators of toll-like receptors for the treatment of hiv
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
JP2017526730A
(ja)
|
2014-09-16 |
2017-09-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
Toll様受容体モジュレーターの固体形態
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
WO2017021911A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
RU2018107693A
(ru)
|
2015-08-04 |
2019-09-05 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Комбинированные виды лечения и их варианты применения и способы
|
EP3331917A1
(en)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
CA2994790A1
(en)
|
2015-08-06 |
2017-02-09 |
Christopher W. Cluff |
Tlr4 agonists and compositions thereof and their use in the treatment of cancer
|
EP3331919A1
(en)
|
2015-08-07 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
EP4015537A1
(en)
|
2015-12-01 |
2022-06-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
MA52157A
(fr)
|
2015-12-03 |
2021-02-17 |
Glaxosmithkline Ip Dev Ltd |
Dinucléotides cycliques de purine utilisés comme modulateurs de sting
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
IL280430B2
(en)
|
2016-03-18 |
2023-11-01 |
Univ Texas |
Cyclic dinucleotide compounds and methods of use
|
EP3440072B1
(en)
|
2016-04-07 |
2020-01-29 |
GlaxoSmithKline Intellectual Property Development Ltd |
Heterocyclic amides useful as protein modulators
|
CR20200045A
(es)
|
2016-04-07 |
2020-03-11 |
Glaxosmithkline Ip Dev Ltd |
AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
|
CN109789135A
(zh)
|
2016-07-20 |
2019-05-21 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为perk抑制剂的异喹啉衍生物
|
EP3494140A1
(en)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos and anti-pd-1 antibody combination therapy
|
EP3512842B1
(en)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
EP3559002A4
(en)
|
2016-12-23 |
2021-02-17 |
Arvinas Operations, Inc. |
CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
|
KR102564201B1
(ko)
|
2016-12-23 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
EP3582855A1
(en)
|
2017-02-15 |
2019-12-25 |
GlaxoSmithKline Intellectual Property Development Limited |
Combination treatment for cancer
|
US11504333B2
(en)
|
2017-07-05 |
2022-11-22 |
Novartis Ag |
Pharmaceutical composition
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
AU2018344902B2
(en)
|
2017-10-05 |
2021-06-03 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING) useful in treating HIV
|
WO2019069270A1
(en)
|
2017-10-05 |
2019-04-11 |
Glaxosmithkline Intellectual Property Development Limited |
GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
US11304930B2
(en)
|
2018-08-07 |
2022-04-19 |
Metagone Biotech Inc. |
Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof
|
KR20210080378A
(ko)
*
|
2018-09-18 |
2021-06-30 |
1글로브 바이오메디칼 씨오., 엘티디. |
비만의 치료
|
AU2019390729B2
(en)
|
2018-11-30 |
2022-08-11 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in HIV therapy
|
AU2020214412A1
(en)
|
2019-02-01 |
2021-08-12 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
EP3969438A1
(en)
|
2019-05-16 |
2022-03-23 |
Stingthera, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
US20220251079A1
(en)
|
2019-05-16 |
2022-08-11 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
CN114222760A
(zh)
|
2019-06-26 |
2022-03-22 |
葛兰素史密斯克莱知识产权发展有限公司 |
Il1rap结合蛋白
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
WO2021046289A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021152495A1
(en)
|
2020-01-28 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
CN114573453A
(zh)
*
|
2020-12-02 |
2022-06-03 |
荆楚理工学院 |
一种选择性的羧酸酯裂解方法
|
KR20240041917A
(ko)
|
2021-07-27 |
2024-04-01 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
KR102566028B1
(ko)
*
|
2021-08-10 |
2023-08-10 |
계명대학교 산학협력단 |
신규한 다중 단백질 키나아제 억제제
|
WO2023230541A1
(en)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Piperazine derivatives useful in hiv therapy
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|